The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2014 | Development of novel agents, including daratumumab and carfilzomib, in myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Philippe Moreau (University Hospital of Nantes, France) discusses novel agents in the management of multiple myeloma.
An open-label, multicentre, phase Ib study of the human anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in multiple myeloma, including bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone, is ongoing.
The phase III ASPIRE study showed that addition of carfilzomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma resulted in a statistically significant improvement in progression-free survival.
